Lirafugratinib Clinical Trials (2026): 1 Studies for FGFR2 Gene Fusion/Rearrangement & Other Solid Tumors, Adult
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
1 Lirafugratinib clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 1 indication (including FGFR2 Gene Fusion/Rearrangement & Other Solid Tumors, Adult) and 30 total planned enrollment. 1 Lirafugratinib clinical trial is actively recruiting at 3 U.S. sites across 3 states. Most recent activity: NCT07359820 (Dec 2028).
Where to Participate: All Lirafugratinib Trial Sites in the U.S. (3 sites across 3 states)
Every actively recruiting Lirafugratinibtrial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.
| State | Facility | City | Trial | Map |
|---|---|---|---|---|
| FL | Moffitt Cancer Center | Tampa33612 | NCT07359820 | Map |
| MA | Massachusetts General Hospital | Boston02114 | NCT07359820 | Map |
| TX | The University of Texas M.D. Anderson Cancer Center | Houston77030 | NCT07359820 | Map |
Lirafugratinib clinical trials at a glance: phase × recruitment status
| Phase | recruiting | Total |
|---|---|---|
| P2 | 1 | 1 |
Recruiting Lirafugratinib clinical trials (1)
Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).
| NCT ID | Title | Phase | Indication | Enrollment | Started |
|---|---|---|---|---|---|
| NCT07359820 | ReFocus202A Study of Lirafugratinib in Non-CCA Solid Tumors With FGFR2 Fusion or Rearrangement | P2 | FGFR2 Gene Fusion/Rearrangement | 30 | Jun 2026 |
Lirafugratinib pivotal trial highlights (Phase 2/3/4)
Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.
| Acronym | NCT | Phase | Status | Indication | Enrollment | PubMed |
|---|---|---|---|---|---|---|
| ReFocus202 | NCT07359820 | P2 | recruiting | FGFR2 Gene Fusion/Rearrangement | 30 | — |
All Lirafugratinib trials (1)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT07359820 | ReFocus202 | A Study of Lirafugratinib in Non-CCA Solid Tumors With FGFR2 Fusion or Rearrangement | P2 | recruiting | 30 | Elevar Therapeutics | Jun 2026 |
Lirafugratinib clinical trials: frequently asked questions
- How many Lirafugratinib clinical trials are there?
- 1 Lirafugratinib clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 1 is actively recruiting participants.
- Are Lirafugratinib clinical trials recruiting in 2026?
- Yes — 1 Lirafugratinib trial is actively recruiting in 2026, with 3 U.S. sites across 3 states. See the recruiting trials and the per-state site list further down this page.
- What conditions is Lirafugratinib being studied for?
- Lirafugratinib is being studied for FGFR2 Gene Fusion/Rearrangement, Other Solid Tumors, Adult. The trials are grouped by indication on this page.
- What phase is Lirafugratinib in?
- Lirafugratinib clinical trials span 1 Phase 2. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors Lirafugratinib clinical trials?
- The lead sponsor across the most Lirafugratinib trials is Elevar Therapeutics. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming Lirafugratinibas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: